Perfil investigador/a: R3. A.2.
Recent Posts
- Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies.
- nvEstigation of the safety and perforMance of the NVT ALLEGRA THV System with a new delivery system in Patients with severe calcified aortIc stenosis or failed suRgical aortic bioprosthEsis
- Non-vitamin K antagonist Oral anticoagulants in patients with Atrial high rate episodes
- New pathophysiological pathways involved in iron metabolism disorder in hear failure: The IRON PATH II investigator initiated Study.
- Modulación de la Contractilidad Cardíaca (CCM©) en Pacientes con Insuficiencia Cardíaca en Andalucía. Registro DOLMEN ART-VIII-2018
Recent Comments
No comments to show.